| Q87988634 | A multicenter prospective study of infections related morbidity and mortality in cirrhosis of liver |
| Q33811004 | Association between proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhotic patients with ascites |
| Q36705999 | Bacterial infections in end-stage liver disease: current challenges and future directions |
| Q35937716 | Bacterial translocation and changes in the intestinal microbiome associated with alcoholic liver disease |
| Q35977446 | Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease |
| Q55322856 | Changes of Intestinal Functions in Liver Cirrhosis. |
| Q36961744 | Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice |
| Q56925275 | Detection of bacterial DNA in serum and ascitic fluid of asymptomatic outpatients with cirrhosis and non-neutrocytic ascites |
| Q64090512 | Effect of proton pump inhibitors on mortality of cirrhotic patients with pneumonia |
| Q28083295 | Gut Microbiota and Host Reaction in Liver Diseases |
| Q55252106 | Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? |
| Q92857451 | Infectious Threats, the Intestinal Barrier, and Its Trojan Horse: Dysbiosis |
| Q33663789 | Inhibition of nitric oxide production reverses diabetes-induced Kupffer cell activation and Klebsiella pneumonia liver translocation |
| Q41036794 | Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications |
| Q28067113 | Intestinal permeability in a patient with liver cirrhosis |
| Q26991664 | Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis |
| Q26783888 | Markers of bacterial translocation in end-stage liver disease |
| Q34482159 | Metformin inhibits glutaminase activity and protects against hepatic encephalopathy |
| Q53234198 | NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. |
| Q39541089 | Oral, intestinal, and skin bacteria in ventral hernia mesh implants |
| Q58701395 | Pathogenesis of hepatic encephalopathy |
| Q38057416 | Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. |
| Q26824138 | Pathological bacterial translocation in liver cirrhosis |
| Q34450128 | Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites. |
| Q36472730 | Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis |
| Q88764776 | Publisher Correction: The gut-liver axis and the intersection with the microbiome |
| Q92435669 | Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications |
| Q37629681 | Risk factors and outcome of bacterial infections in cirrhosis |
| Q38062486 | Role of diabetes mellitus on hepatic encephalopathy |
| Q57027234 | Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis |
| Q34861969 | Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective β-blockers. |
| Q59353836 | The Immunologic Role of Gut Microbiota in Patients with Chronic HBV Infection |
| Q34474989 | The dormant blood microbiome in chronic, inflammatory diseases |
| Q88634168 | The gut-liver axis and the intersection with the microbiome |
| Q36310293 | The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease |